Suppr超能文献

欧洲肥胖症研究学会立场声明:育龄期肥胖女性——生育力、孕前、孕期、产后及母乳喂养

EASO Position Statement: Women with Obesity across the Reproductive Life - Fertility, Preconception, Pregnancy, Postpartum, and Breastfeeding.

作者信息

Filippi-Arriaga Francesca, Agarwal Nidhi, Rodrigues-Martins Diana, Monteiro Mariana P, Huvinen Emilia, Suliman Sara G I, McGowan Barbara, Ciudin Andreea

机构信息

Endocrinology and Nutrition Department, Obesity Unit, Vall Hebron University Hospital, Barcelona, Spain,

Endocrinology, Obesity and Bariatric Department, Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.

出版信息

Obes Facts. 2025 Jun 21:1-15. doi: 10.1159/000546449.

Abstract

BACKGROUND

Obesity management in women presents distinct challenges across their lifespan. However, there is limited evidence or recommendations focused solely on women living with obesity.

SUMMARY

This European Association for the Study of Obesity (EASO) position statement is based on an expert comprehensive review and summary of the available scientific evidence on women living with obesity. It aims to guide the health and medical assessment of these women during their reproductive life (fertility, preconception, pregnancy, postpartum, and breastfeeding).

KEY MESSAGES

  1. To better diagnose obesity in women beyond BMI, the use of at least one additional anthropometric measure, like waist-to-height ratio (WHtR), is strongly recommended. When available, the use of bioelectrical impedance vector analysis is encouraged. 2. Women with obesity should be offered obesity management counseling and psychological support. 3. Obesity can negatively impact fertility; weight loss of 5-10% over 6 months improves fertility. 4. In women with Polycystic Ovary Syndrome (PCOS), treatment with metformin and GLP-1 receptor agonists or surgery can be considered. 5. Current recommendations for pregestational obesity suggest a gestational weight gain (GWG) of 5-9 kg. Lower GWG targets should be considered, particularly for class II or III obesity. 6. There is limited clinical data on the safety and efficacy of obesity medication during pregnancy or lactation. 7. All pregnant women with obesity should be offered prenatal screening for fetal anomalies, with discussion of the potential limitations of diagnostic tests and additional growth ultrasounds offered on an individual basis. 8. All pregnant women with a BMI ≥30 kg/m2 should be screened for gestational diabetes in early pregnancy. Measures to prevent preeclampsia should be taken and the need for thromboprophylaxis assessed. 9. Intrapartum fetal surveillance is recommended during active labor. 10. Postpartum weight management is needed to mitigate the risk of adverse outcomes for the mother and for subsequent pregnancies. The assessment of appropriate contraceptive methods during the postpartum and breastfeeding period is crucial.
摘要

背景

女性肥胖管理在其一生中面临着独特的挑战。然而,仅有有限的证据或建议专门针对肥胖女性。

总结

本欧洲肥胖研究协会(EASO)立场声明基于对肥胖女性现有科学证据的专家全面审查和总结。其目的是指导这些女性在生殖期(生育、孕前、孕期、产后和哺乳期)的健康和医学评估。

关键信息

  1. 为了在BMI之外更好地诊断女性肥胖,强烈建议至少使用一种额外的人体测量指标,如腰高比(WHtR)。如有条件,鼓励使用生物电阻抗矢量分析。2. 应为肥胖女性提供肥胖管理咨询和心理支持。3. 肥胖会对生育能力产生负面影响;在6个月内减重5 - 10%可提高生育能力。4. 对于多囊卵巢综合征(PCOS)女性,可考虑使用二甲双胍和GLP - 1受体激动剂治疗或手术治疗。5. 当前关于孕前肥胖的建议表明孕期体重增加(GWG)应为5 - 9千克。应考虑更低的GWG目标,特别是对于II级或III级肥胖者。6. 关于孕期或哺乳期肥胖药物的安全性和有效性的临床数据有限。7. 所有肥胖孕妇都应接受胎儿异常的产前筛查,并讨论诊断测试的潜在局限性以及根据个体情况提供额外的生长超声检查。8. 所有BMI≥30 kg/m²的孕妇应在孕早期筛查妊娠期糖尿病。应采取预防子痫前期的措施并评估血栓预防的必要性。9. 建议在活跃期分娩时进行产时胎儿监测。10. 需要进行产后体重管理以降低母亲及后续妊娠不良结局的风险。评估产后和哺乳期合适的避孕方法至关重要。
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/428b/12306975/af05d4823b2e/ofa-2025-0000-0000-546449_F01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验